Influence of digital rectal massage on urinary prostate-specific antigen: Interest for the detection of local recurrence after radical prostatectomy

Malavaud, Bernard; Salama, Gilles; Miédougé, Marcel; Vincent, Christian; Rischmann, P.; Sarramon, Jean‐Pierre; Serre, Guy

doi:10.1002/(sici)1097-0045(19980101)34:1<23::aid-pros3>3.0.co;2-l

Cited by 19 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over the years, PSA has been measured on different samples: in urine voided before and after prostate massage, 3,4 in first-voided urine, [4][5][6] in single midstream sample of urine [7][8][9][10] and in 24-hour urine specimens. [11][12][13] The fact that a urine specimen contains more PSA certainly appears to be an advantageous issue in terms of method of choice for PSA measurement.…”

mentioning

confidence: 99%

Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL

Bolduc

Lacombe

Naud

et al. 2013

CUAJ

View full text Add to dashboard Cite

Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL ORIGINAL RESEARCH Abstract Introduction: Our objective was to evaluate the usefulness of urinary prostate specific antigen (PSA) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer. Methods:We undertook a prospective study and obtained informed consent from 170 men. They provided blood samples to measure serum PSA and 50 mL of firstvoided urine to measure urinary PSA. Seventy-seven men were diagnosed with BPH; 42 patients had newly diagnosed prostate cancer; and 51 were selected as age-matched control subjects. Data were analyzed using Wilcoxon signed rank tests, receiver operating characteristic (ROC) curves and logistic regression. Results:Prostate volume was 35 cm 3 and 45 cm 3 (p < 0.05), serum PSA was 9.7 ng/mL and 4.5 ng/mL (p < 0.001) and PSA density was 0.28 and 0.11 (p < 0.01) for prostate cancer and BPH patients, respectively. Overall, urinary PSA was not significantly different, but PSA ratio (urinary:serum) was significantly different at 6.7 and 30.6 (p < 0.001) for prostate cancer and BPH patients, respectively. A subgroup with serum PSA between 2.5 ng/mL and 10.0 ng/mL was selected and urinary PSA was significant: 52.6 ng/mL (n = 29) and 123.2 ng/mL (n = 35) (p < 0.05) for prostate cancer and BPH patients, respectively. PSA ratios were also significant (p = 0.007). ROC curves identified a cutoff for urinary PSA at > 150 ng/mL, with a sensitivity of 92.5%. When comparing prostate cancer patients with age-matched control subjects, serum PSA, urinary PSA and PSA ratio were different (p = 0.004). Conclusion:Our study supports urinary PSA as a useful marker in the differential diagnosis of prostate cancer and BPH, especially when serum PSA is between 2.5 ng/mL and 10 ng/mL. Low urinary PSA and PSA ratios point toward prostate cancer. A urinary PSA threshold of > 150 ng/mL may be used to decrease the number of prostatic biopsies. IntroductionSerum prostatic specific antigen (PSA) has proven to be a generally reliable indicator in the diagnosis and management of prostate cancer. It has revolutionized the management and follow-up of prostate cancer since its clinical introduction in the late 1980s. Serum PSA remains the best single test for the detection of early prostate cancer, and multiple variations have been studied to improve its sensitivity and speci- either urinary tract infection or symptoms of prostatitis. Patients were consecutively recruited during a scheduled clinic visit either before a transrectal ultrasound (TRUS) and biopsies (minimum of 8 core biopsies) for abnormal serum PSA or digital rectal exam (or both); or patients who had an established diagnosis of prostate cancer were recruited for participation when they presented for preadmission before a scheduled radical prostatectomy.A total of 170 men gave an informed written consent and provided blood samples to measure serum PSA and bioavailable testosterone (normal range 2-14 nmol/L), which was analyzed in our labor...

show abstract

mentioning

confidence: 99%

Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL

Bolduc

Lacombe

Naud

et al. 2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Algunos grupos intentaron evaluar, sin éxito, si la medición del PSA en orina podría ayudar al diagnóstico de una recidiva local 27 . Probablemente el fracaso de dichos trabajos residía en que el epitelio de las glándulas paruretrales también sintetiza esta proteína 28 .…”

Section: Resultados Y Discusiónunclassified

“…Probablemente el fracaso de dichos trabajos residía en que el epitelio de las glándulas paruretrales también sintetiza esta proteína 28 . Posteriormente se planteo la posibilidad de medir el PSA total y la fracción libre del PSA en orina antes y tras el masaje de la anastomosis 27 . Los primeros resultados parecían prometedores, la medición de la fracción libre de PSA en el chorro miccional medio permitiría distinguir una recidiva tumoral local de una recidiva hiperplásica.…”

Section: Resultados Y Discusiónunclassified

Trascendencia de células hiperplásicas residuales a la prostatectomía radical: Revisión de la Literatura

et al. 2008

View full text Add to dashboard Cite

Introducción: La Prostatectomía radical es el tratamiento estándar para el cáncer de próstata organoconfinado. Clásicamente se presta atención a los márgenes positivos para células tumorales, pero no a la presencia de células hiperplásicas residuales a la cirugía capaces de generar antígeno prostático específico (PSA) y dificultar el seguimiento de los pacientes intervenidos. Esta situación nos lleva a plantear una revisión de la literatura, donde evaluemos la frecuencia de esta presencia, las posibles causas que lo justifiquen y la influencia de estas células en la evolución bioquímica de la enfermedad.Material y Método: Realizamos una búsqueda bibliográfica a través de la base de datos "Pubmed" utilizando los tér-minos "Mesh" "Prostatectomy" y "Prostatic Neoplasms" y "Prostate-Specific Antigen" a los que añadimos los términos "biochemical failure" y/o "hyperplasic cells" y/o "benign cells" . Asímismo, seleccionamos los trabajos en lengua inglesa, española y alemana, revisamos los artículos que dichos trabajos referencian e incluimos las series con más de 50 pacientes, cartas al editor, editoriales y revisiones de conjunto.Conclusiones: La presencia de células hiperplásicas microscópicas residuales a la cirugía prostática radical, es un hecho frecuente que probablemente esté infra-evaluado. Los márgenes positivos para células benignas procederán del ápex o del cuello vesical donde la cápsula prostática no está bien definida, en ningún caso de la zona dorsolateral de la próstata, lo que traduciría un defecto de la técnica quirúrgica. La capacidad de estas células para generar PSA en cantidad suficiente para interferir en el seguimiento de los pacientes operados es controvertida. Recomendamos la inspección macroscópica de la pieza por el cirujano, tras la prostatectomía, para evaluar la integridad del ápex, zona craneal y cápsula dorsolateral.Palabras clave: Cáncer de próstata. Prostatectomía radical. Células prostáticas hiperplásicas. ABSTRACT SIGNIFICANCE OF RESIDUAL HYPERPLASTIC CELLS AFTER RADICAL PROSTATECTOMY. A LITERATURE REVIEWIntroduction: Radical prostatectomy represents a standard surgical treatment for clinically localized prostate cancer. Classically pathologist and urologist worried about positive surgical margin, but not to the presence of surgery residual hyperplastic cells able to generate prostate specific antigen (PSA) and difficult the follow up of the patients that underwent surgery.We reviewed the literature looking for the incidence, the potential etiology and the influence of these hyperplastic cells in the biochemical evolution of the disease.Material and Method: The information for this review was compiled by searching the Pubmed database. We used "Mesh", Prostatectomy" and "Prostatic Neoplasms" and "Prostate-Specific Antigen" terms, and we added "biochemical failure" and/or "hyperplasic cells" and/or "benign cells". Furthermore, we select the work in English, Spanish and German, review articles that referenced this work and include the series with more than 50 patients, letters to the e...

show abstract

“…Therefore, it is necessary to identify and remove proteins that are from the urinary system among proteins found in urine, in order to identify biomarkers for diseases in distal organs [3]. Currently, the most useful disease markers in urine have been largely for urogenital diseases, such as urothelial cancer [4], renal cell carcinoma [5], prostate cancer [6], and bladder cancer [7]. A few recent studies have demonstrated the feasibility in using urinary proteins as disease markers in distal organs, such as ovarian carcinoma [8], lung cancer [9], hepatocellular carcinoma [10], and gastric cancer [11].…”

Section: Introductionmentioning

confidence: 99%

PUEPro: A Computational Pipeline for Prediction of Urine Excretory Proteins

Wang

Liang

et al. 2016

Advanced Data Mining and Applications

View full text Add to dashboard Cite

Abstract.A computational pipeline is developed to accurately predict urine excretory proteins and the possible origins of the proteins. The novel contributions of this study include: (i) a new method for predicting if a cellular protein is urine excretory based on unique features of proteins known to be urine excretory; and (ii) a novel method for identifying urinary proteins originating from the urinary system. By integrating these tools, our computational pipeline is capable of predicting the origin of a detected urinary protein, hence offering a novel tool for predicting potential biomarkers of a specific disease, which may have some of their proteins urine excreted. One application is presented for this prediction pipeline to demonstrate the effectiveness of its prediction. The pipeline and supplementary materials can be accessed at the following URL:

show abstract

Influence of digital rectal massage on urinary prostate-specific antigen: Interest for the detection of local recurrence after radical prostatectomy

Cited by 19 publications

References 19 publications

Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL

Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL

Trascendencia de células hiperplásicas residuales a la prostatectomía radical: Revisión de la Literatura

PUEPro: A Computational Pipeline for Prediction of Urine Excretory Proteins

Contact Info

Product

Resources

About